obesity

News

Compounders cast adrift after semaglutide shortage ends

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

Digital

Looking beyond the scale: Why measures of physical activity ...

GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.

R&D

Will 2025 be the year the pharmaceutical industry finds its ...

After spending 2024 in recovery mode, the biopharma industry is finally showing signs of growth, climbing back toward its pre-pandemic heights.

News

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."

News

Martin Holst Lange, Novo Nordisk's head of development

Novo charts course ahead for CagriSema after lacklustre data

After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track.

News

Novo rises on Wegovy sales leap, but warns of a slowdown

Novo Nordisk is expecting greater competition and pricing pressure in the obesity and diabetes sectors this year.

Compounders cast adrift after semaglutide shortage ends

Looking beyond the scale: Why measures of physical activity ...

Will 2025 be the year the pharmaceutical industry finds its ...

Pharma group slams Hims & Hers over Super Bowl GLP-1 ad

Novo charts course ahead for CagriSema after lacklustre data

Novo rises on Wegovy sales leap, but warns of a slowdown

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

obesity

Editor's Picks